EUVIMEDEUVIMED entdecken
Crossref

Brain-penetrant cyanoindane and cyanotetralin inhibitors of G2019S-LRRK2 kinase activity

Albert W Garofalo, Jacob Schwarz, Kerry Zobel, Claudia Beato, Silvia Bernardi, Federica Budassi, Laura Caberlotto, Peng Gao, Cristiana Griffante, Xinying Liu, Marco Migliore, Feifei Qiao und 4 weitere

Bioorganic & Medicinal Chemistry Letters · 2023-10 · 95 · 129487

DOI: 10.1016/j.bmcl.2023.129487 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2023-10. Verfasst von Albert W Garofalo und 15 weiteren Autor:innen. Beteiligte Einrichtung: ESCAPE Bio, South San Francisco, CA 94080, United States. Electronic address: albert6@stanford.edu. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Brain, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Indans. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 7 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The G2019S variant of LRRK2, which causes an increase in kinase activity, is associated with the occurrence of Parkinson's disease (PD). Potent, mutation-selective, and brain penetrant inhibitors of LRRK2 can suppress the biological effects specific to G2019S-LRRK2 that cause pathogenicity. We report the discovery of a series of cyanoindane and cyanotetralin kinase inhibitors culminating in compound 34 that demonstrated selective inhibition of phosphorylation of LRRK2 in the mouse brain. These novel inhibitors may further enable the precision medicine path for future PD therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsBrainLeucine-Rich Repeat Serine-Threonine Protein Kinase-2IndansNitrilesAnimalsMiceHumansStructure-Activity RelationshipMolecular StructurePhosphorylationDose-Response Relationship, DrugParkinson Disease

Stichwörter der Autor:innen

G2019SKinase inhibitorLRRK2Parkinson’s disease

Substanzen

Protein Kinase InhibitorsLeucine-Rich Repeat Serine-Threonine Protein Kinase-2IndansNitriles

Autor:innen und Institutionen

  • ESCAPE Bio, South San Francisco, CA 94080, United States. Electronic address: albert6@stanford.edu.
  • ESCAPE Bio, South San Francisco, CA 94080, United States.
  • Aptuit, an Evotec Company, 37135 Verona, Italy.
  • WuXi AppTec, Tianjin 300456, PR China.

Zitieren

APA

Garofalo, A. W., Schwarz, J., Zobel, K., Beato, C., Bernardi, S., Budassi, F., Caberlotto, L., Gao, P., Griffante, C., Liu, X., Migliore, M., Qiao, F., Sabbatini, F. M., Sava, A., Zhang, M., & Carlisle, H. J. (2023). Brain-penetrant cyanoindane and cyanotetralin inhibitors of G2019S-LRRK2 kinase activity. Bioorganic & Medicinal Chemistry Letters, 95, 129487. https://doi.org/10.1016/j.bmcl.2023.129487

Vancouver

Garofalo AW, Schwarz J, Zobel K, Beato C, Bernardi S, Budassi F, et al. Brain-penetrant cyanoindane and cyanotetralin inhibitors of G2019S-LRRK2 kinase activity. Bioorganic & Medicinal Chemistry Letters. 2023;95:129487. doi:10.1016/j.bmcl.2023.129487

BibTeX
@article{Garofalo2023,
  author = {Garofalo, Albert W and Schwarz, Jacob and Zobel, Kerry and Beato, Claudia and Bernardi, Silvia and Budassi, Federica and Caberlotto, Laura and Gao, Peng and Griffante, Cristiana and Liu, Xinying and Migliore, Marco and Qiao, Feifei and Sabbatini, Fabio Maria and Sava, Anna and Zhang, Mingliang and Carlisle, Holly J},
  title = {Brain-penetrant cyanoindane and cyanotetralin inhibitors of G2019S-LRRK2 kinase activity},
  journal = {Bioorganic & Medicinal Chemistry Letters},
  year = {2023},
  volume = {95},
  pages = {129487},
  doi = {10.1016/j.bmcl.2023.129487}
}
Kostenlos starten →